Committed to innovation and growth

Transcription

1 Committed to innovation and growth Alan Hippe, CFO Roche Group New York, February 2013

2 Premium for innovation Roche strategy: Focused on medically differentiated therapies Pharma Dia Regulators: Optimised benefit / risk ratio Focus Payors: Optimised benefit / cost ratio MedTech Generics OTC Differentiation 2

3 Roche: Operating profit and margin continuously increased Group core operating profit and margin 33.0% 33.2% 34.9% 35.6% +11% % % of sales CHF bn 1 At CER=Constant Exchange Rates

4 Roche: Cash flow and margin continuously increased Group operating free cash flow and margin 27.1% 32.1% 29.8% 32.3% +10% % % of sales CHF bn 1 At CER=Constant Exchange Rates

5 R&D productivity differs substantially among players Average annual NME peak sales ( ) 1 US$ bn $ 710 m Peak Sales (per $1 bn R&D) 4 x Roche $ 165 m Peak Sales (per $1 bn R&D) Average annual R&D investment ( ) 1 US$ bn 1 Peak sales and R&D calculated pro forma to account for major M&A Source: EvaluatePharma; BCG analysis; Roche analysis 5

6 Roche: R&D well balanced from a risk & disease point of view 2012 Roche budget Oncology Metabolism Inflammation CNS Virology 0% 5% 10% 15% 20% 25% 30% Industry average probability of success Phase 0 to Registration Source: Bernstein Equity Research, Tufts University and Roche analysis 6

7 Changing the standard of care in HER2 Securing future growth by improving the standard of care Biosimilars launch (EU) 2nd line mbc Xeloda + lapatinib T-DM1 (EMILIA) 1st line mbc Herceptin + chemo Herceptin & Perjeta + chemo (CLEOPATRA) T-DM1 & Perjeta (MARIANNE) Adjuvant BC Herceptin + chemo Herceptin subcutaneous + chemo (HannaH) Herceptin & Perjeta + chemo (APHINITY) T-DM1 & Perjeta + chemo Filing timelines Established standard of care Potential new standard of care Potential future standard of care 7

8 Changing the standard of care in hematology Different mechanisms of action Potential filing of first indication MabThera Rituxan* GA Bcl-2 Anti-CD22 ADC Anti-CD79b ADC * Patent expiry in the US:

9 Best-in-class pipeline 71 NMEs supporting long-term growth MDM2 ant HER3 MAb CSF-1R MAb CIF/MEK inh Tweak MAb CD44 MAb Ang2-VEGF MAb Raf & MEK dual inh MEK inh MDM2 ant AKT inhibitor PD-L1 MAb Steap 1ADC ADC ADC ADC ADC solid & hem tumors oncology oncoloy solid & hem tumors prostate ca. ovarian ca. heme tumors multiple myeloma oncology Phase I (36 NMEs) Bcl-2 inh ChK1 inh PI3K inh ADC PI3k inh ChK1 inh(2) ALK inhibitor PI3K inh WT-1 peptide IL-17 MAb IL-6 MAb CIM331RA TLR7 agonist GIP/GLP-1 dual ago GABRA5 NAM V1 receptor antag BACE inh PDE inh ACE910 CLL and NHL solid tum & lymphoma metastatic melanoma glioblastoma 2L NSCLC cancer vaccine autoimmune diseases RA atopic dermatitis HBV type 2 diabetes cogn. disorders autism Alzheimer s schizophrenia hemophilia A Phase II (23 NMEs) EGFR MAb PI3K inh PI3K/mTOR inh solid & hem tumors EGFL7 MAb CD22 ADC heme tumors CD79b ADC heme tumors HER3/EGFR m. epithelial tumors glypican-3 MAb liver cancer etrolizumab ulcerative colitis rontalizumab SLE quilizumab (M1 prime Mab) asthma mericitabine HCV danoprevir HCV setrobuvir HCV - CMV inclaumab (P selectin Mab) ACS/CVD PCSK9 MAb metabolic diseases gantenerumab Alzheimer s MAO-B inh Alzheimer s mglur2 antag depression mglur5 antag TRD crenezumab Alzheimer s anti-factor D Fab geograph. atrophy Phase III (9 NMEs) onartuzumab (MetMAb) obinutuzumab (GA101) hem. tumors MEK inh combo Zelboraf m. melanoma lebrikizumab severe asthma aleglitazar CV risk reduction in T2D tofogliflozin (SGLT2) type 2 diabetes ocrelizumab MS bitopertin schizophrenia arbaclofen Registration (3 NMEs) Perjeta (pertuzumab)* Erivedge* T-DM1 fragile X syndrome (FXS) HER2+ mbc 1L advanced BCC HER2+ mbc As of December ; * Approved in US, filed in EU Oncology Immunology Virology CardioMetabolism Neuroscience Ophthalmology Others 9

10 2012: US and Emerging markets driving growth Pharma Growth vs. market Diagnostics Growth vs. market Asia 15% Asia- Pacific 15% Latin America 11% Latin America 15% CEMAI 8% US 7% North America 3% Japan 2% Japan 7% WE -2% EMEA -1% All growth rates at CER=Constant Exchange Rates; CEMAI=Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent; EMEA=Europe, Middle East and Africa. Source: IMS, company and independent estimates 10

11 Summary: Focus on innovation and growth 1 Strategic focus on innovation and driving Personalised Healthcare 2 Strong growth in US and Emerging Markets; innovative access models 3 Leading product pipeline providing value for the future 11

12 We Innovate Healthcare